Journal
SEMINARS IN ARTHRITIS AND RHEUMATISM
Volume 56, Issue -, Pages -Publisher
W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.semarthrit.2022.152052
Keywords
Systemic sclerosis; Scleroderma; Scl-70 antibody; Topoisomerase I antibody; ANA; Immunodiffusion
Categories
Funding
- National Institutes of Health [RO1AR073284]
- Arthritis Na-tional Research Foundation
Ask authors/readers for more resources
In clinical practice, commonly used commercial laboratories' assays for anti-Scl-70 antibody can produce false positive results, leading to unnecessary referrals and diagnostic evaluations.
Purpose: To determine if some patients who tested positive for anti-Scl-70 antibody in clinical practice, but did not have classifiable systemic sclerosis, were negative for anti-Scl-70 antibody by the more specific immunodiffusion method of testing. Methods: Patients evaluated by a rheumatologist at a Scleroderma referral center who had tested positive for antiScl-70 antibody prior to referral, but did not have classifiable SSc based on clinical criteria, were invited to undergo testing for anti-Scl-70 antibody by immunodiffusion. Patient demographics and clinical features were recorded at the time of their evaluation, and diagnostic testing results were reviewed using the medical records. Results: 52 patients were enrolled over an 8-year period, with 48 (92.3%) testing negative and 4 (7.7%) testing positive for anti-Scl-70 antibody by immunodiffusion. Of the 48 patients who tested negative, 18 (37.5%) tested negative for ANA by indirect immunofluorescence, 33 (68.8%) did not have Raynaud's phenomenon, and 43 (89.6%) had <= 1 clinical criteria items based on the 2013 ACR/EULAR SSc classification criteria. Nevertheless, 21 (43.8%) patients who were negative for anti-Scl-70 antibody by immunodiffusion had undergone a chest CT and 14 (29.2%) had undergone an echocardiogram. A total of 23 patients had at least one follow up clinic visit. 3 out of 4 patients who were positive for anti-Scl-70 antibody by immunodiffusion, but none of the 19 patients who tested negative by immunodiffusion, developed sufficient criteria during follow up to be classified as SSc. Conclusion: Assays for anti-Scl-70 antibody in commercial laboratories that are commonly utilized in clinical practice can produce false positive results. These results can lead to angst for patients, as well as unnecessary referrals and diagnostic evaluations.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available